Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31492896 | 0.90 | GAA (0.43) | AKT1ALDH1A1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL15632547 | 0.85 | NOTUM (0.56) | AKT1POLBNOTUM | |
| SCHEMBL31016655 | 0.85 | AKT1 (0.43) | AKT1STAT3ALDH1A1SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL15648804 | 0.83 | NOTUM (0.54) | AKT1POLBNOTUM | |
| SCHEMBL25629843 | 0.82 | CYP11B1 (0.51) | AKT1ALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL27742432 | 0.80 | LMNA (0.43) | STAT3ALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL758787 | 0.77 | POLB (0.47) | AKT1MAPTPOLB | |
| SCHEMBL30900485 | 0.77 | POLB (0.47) | AKT1MAPTPOLB | |
| SCHEMBL16823475 | 0.76 | CYP11B2 (0.45) | ALDH1A1SMN1; SMN2LMNAMAPTMEN1 | |
| SCHEMBL31663935 | 0.76 | CYP11B2 (0.45) | ALDH1A1SMN1; SMN2LMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12522587-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| CN-119775198-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-112312899-B | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-117917406-A | Heterocyclic compounds, process for their preparation and their use | 四川科伦博泰生物医药股份有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-115836064-A | Triazine derivative with EGFR (epidermal growth factor receptor) inhibitory activity and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20220324842-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3787612-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | Remedy Plan, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112312899-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-105829310-A | Bicyclic heterocyclic compounds and their therapeutic use | 阿斯特克斯治疗有限公司 | 2016-08-03 | — | — | CN | disclosed |
| EP-2427450-A1 | GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2427448-A1 | Gpr 119 modulators | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052130-A1 | GPR 119 MODULATORS | GPR119, GPR39, GPR65 | AKT1 3042/4885STAT3 2275/4885ALDH1A1 1763/4885 |
| US-20100285145-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | AKT1 2697/4885STAT3 2567/4885ALDH1A1 1516/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | AKT1 1738/4885STAT3 848/4885ALDH1A1 56/4885 |
| US-20220324842-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, CD47, GLI1 | AKT1 865/4885STAT3 359/4885ALDH1A1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.